Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Table 1

Patient characteristics.

	N = 43
Median age (years, range)	70 (39–91)
Female (n (%))	18 (42)
Histologic subtype (n (%))
Papillary	10 (23)
Follicular	26 (61)
Poorly differentiated	4 (9)
Anaplastic and follicular	2 (5)
Anaplastic	1 (2)
Metastatic lesions (n (%))
Pulmonary metastases	37 (86)
Bone metastases	15 (35)
Lymph node metastases	32 (74)
Liver metastases	7 (16)
Brain metastases	5 (12)
Soft tissue metastases	11 (26)
Prior radioiodine therapy (n (%))
None	2 (5)
One	10 (23)
Two	13 (30)
Three	7 (16)
Four	6 (14)
More than four	5 (12)
Median radioiodine activity (MBq, range)	11100 (1780–41277)
Prior TKI therapy
Yes	8 (19)
No	35 (81)